MAIA Biotechnology (MAIA) Q3 2024 earnings summary

Executive summary

• MAIA Biotechnology is a clinical-stage biotech focused on telomere-targeting cancer therapies, with lead asset THIO in Phase 2 trials for NSCLC and multiple Orphan Drug Designations from the FDA.

• Key milestones include positive interim efficacy and safety data for THIO, completion of Phase 2 trial enrollment, and ongoing expansion into additional cancer indications.

• The company raised over $12M year-to-date through private placements and at-the-market offerings, with continued insider participation.

Financial highlights

• Net loss for Q3 2024 was $2.74M, a 44% improvement compared to $4.88M in Q3 2023; net loss for the nine months ended September 30, 2024 was $19.68M, up 46% from $13.52M in the prior year period.

• Operating expenses for Q3 2024 were $4.19M, down 15% year-over-year; for the nine months, operating expenses were $11.95M, down 13% year-over-year.

• Cash as of September 30, 2024 was $8.69M, up from $7.15M at year-end 2023; working capital was $5.63M, up from $2.63M at year-end.

• Other income in Q3 2024 increased to $1.45M, mainly due to changes in fair value of warrant liabilities.

Outlook and guidance

• Management expects continued operating losses and negative cash flows due to ongoing clinical trial expenditures and lack of revenue.

• Additional capital will be required to fund operations and future product development; there is substantial doubt about the company's ability to continue as a going concern within one year without further financing.